45 results about "Taurolidine" patented technology

Treating of localized bacterial infection, comprising locally applying Taurolidine to the infection. A device for insertion into the body, the device comprising Taurolidine to render the device infection resistant. A medication for treating bacterial infections, comprising Taurolidine carried by one of: gels, liquid, thixotropic gels, colloidal mixtures, dispensal suspensions, injectable polymers, or a microparticle. A method for treating blood, comprising: removing blood from the body; treating the blood with Taurolidine; and returning the treated blood.

An antiseptic preparation is provided for the production of wound dressings or bandages. The preparation includes at least one alginate and at least one antiseptically active substance selected from the group biguanide derivatives, octenidine and taurolidine. Processes for the production of the antiseptic preparations, and the use thereof, are also provided.

The invention provides a method of inhibiting tumor growth in a mammal, by administering to the mammal composition containing taurolidine, taurultam, or a biologically active derivative thereof. The composition is administered to directly contact a tumor cell at a dose sufficient to induce cell death by apoptosis.

The invention provides a quality detection method for Taurolidine. The method uses thin-layer chromatography, gas phase chromatography and titering process to detect the quality of the Taurolidiene. The quality detection method for Taurolidine has the advantages of rapidness, accuracy, convenient operation and excellent reproduction quality, and ensures the product quality of the Taurolidine.

Compositions and methods are provided for preventing formation of thrombosis on a liquid-contacting surface of a liquid delivery system, such as a port, catheter or port-catheter system. The liquid delivery system is connected to a patient for delivery of a liquid to the patient. The method involves contacting the surface with a thrombosis-preventing liquid containing taurolidine, taurultam or a mixture thereof, the thrombosis-preventing liquid further containing an anticoagulant agent. In an alternative embodiment, the liquid-contacting surface of the delivery system is contacted with a solution containing an anticoagulant agent, and thereafter contacted with a solution containing taurolidine, taurultam or a mixture thereof.

Treatment of a skin disease selected from acne, rosacea, atopical dermatitis, and various ulcers, by topically applying a suitable pharmaceutical composition containing an effective amount of taurolidine, taurultam or a mixture containing both.

Tumor growth and metastases in cancer patients are inhibited by administration of a combination therapy including effective amounts of 5-Fluorouracil and a methylol transfer agent such as taurolidine, taurultam or mixtures thereof.

Novel antimicrobial compositions and coatings are disclosed. The antimicrobial compositions consist of mixtures of taurolidine and protamine, including protamine salts. The antimicrobial compositions are particularly useful in coatings for implantable medical devices. The antimicrobial compositions are effective against a broad spectrum of microbes.

A therapeutic nanoparticle comprising: at least one oncologic drug; and taurolidine, whereby to provide the simultaneous delivery of the at least one oncologic drug and taurolidine, thereby harnessing the synergistic effect of taurolidine on the at least one oncologic drug.

An antiseptic preparation is provided for the production of wound dressings or bandages. The preparation includes at least one alginate and at least one antiseptically active substance selected from the group biguanide derivatives, octenidine and taurolidine. Processes for the production of the antiseptic preparations, and the use thereof, are also provided.

Placement of a vascular access device (intravenous, intra-arterial and / or intra-osseous vascular access) in a non-sterile environment greatly increases the risk of infection via the vascular access device. This invention provides an approach for accomplishing sterilization of the site where vascular access will be attempted under non-sterile field conditions. In addition, this invention provides a sterile vascular connector pre-loaded with an antimicrobial, e.g., Taurolidine. Use of the vascular connector provides the antimicrobial concurrently with achieving vascular access, which limits the risk of infection despite access placement under non-sterile field conditions.

The invention discloses application of a compound in the aspect of antiviral drugs, and particularly relates to application of taurolidine to a drug for treating and preventing novel coronaviruses or influenza viruses. The drug is a drug for preventing and treating pulmonary diseases caused by viruses. The viruses include RNA viruses such as influenza viruses and coronaviruses. According to the invention, the effect range of the taurolidine is expanded, it is proved that replication of influenza viruses and SARS-CoV-2 can be remarkably inhibited at the cellular level, it is indicated that the taurolidine has a very positive inhibiting effect on the influenza viruses and SARS-CoV-2, and a research basis is provided and a new direction is opened up for preparing the drug for preventing and treating pulmonary infections caused by the influenza viruses and novel coronaviruses. Moreover, It is proved by in-vitro experiments that the taurolidine has a remarkable protection effect on lungs, can prolong the survival time of mice infected with the influenza viruses, and can be used for preventing and treating the pulmonary diseases caused by the influenza viruses.

A composition comprising: hydrolysable taurolidine; and a hydrolysable lipophilic excipient; wherein the hydrolysable taurolidine is contained within the hydrolysable lipophilic excipient.

The invention discloses application of taurolidine in preparation of anti-coronavirus drugs, and relates to the technical field of medicines. The new application of taurolidine is discovered for the first time, namely the application of taurolidine in inhibition of coronavirus or in preparation of anti-coronavirus drugs, and coronavirus is HCoV-229E, HCoV-OC43, SARS-CoV, HCoV-NL63, HCoV-HKU1 or MERS-CoV. The safety of taurolidine to a human body is detected through clinical practice, the obvious drug effect of taurolidine to coronavirus is found, a powerful theoretical basis and a practical basis are provided for coronavirus resistance, and the taurolidine has development value and popularization significance. The invention provides a new way for treating diseases caused by coronavirus infection.

An antimicrobial suture comprising a filament and taurolidine.

Methods and compositions for the treatment and / or prophylaxis and / or suppression of primary and / or secondary tumors of the central nervous system (brain and spinal cord, eyes) in mammalian subjects are disclosed, wherein an effective dose of a methylol transfer agent such as Taurolidine and / or Taurultam and / or a bioequivalent is administered to a mammalian subject suffering from, or at risk of growth of, tumors of the central nervous system. Furthermore, methods for local application of Taurolidine and / or Taurultam and / or a bioequivalent in solution are disclosed using microdialysis methods, irrigation methods, implantion methods and angiographic methods.

It now has been found that oral administration of pharmaceutical agents, including N-methylol transfer agents such as Taurolidine may be used to provide efficacious blood plasma concentration of the agents for treatment of diseases by providing release of the active agent into the duodenum or jejunum of a patient and / or at a pH of about 5.4 to about 6.5. Embodiments of the invention therefore provide oral dosage forms, compositions and methods for administration of pharmaceutical agents to the duodenum or jejunum of a patient, and / or which release at a pH of about 5.4 to about 6.5.

The invention relates to an application of taurolidine in preparation of anti-HIV virus drugs, and relates to the technical field of medicines. The new application of taurolidine is discovered for thefirst time, namely the application of taurolidine in inhibition of HIV virus or in preparation of HIV virus drugs. The safety of taurolidine to a human body is detected by clinical practice, the obvious drug effect of taurolidine on HIV virus is discovered, powerful theoretical basis and practical basis are provided for anti-HIV virus, and the taurolidine has development value and popularizationsignificance. According to the application, the inactivation effect of taurolidine on human immunodeficiency virus HIV is detected on a cellular level, and the inactivation efficiency is about 73%. The invention provides a new way for treatment of AIDS.

The invention provides an application of taurolidine in virus resistance. Specifically, the invention provides use of the taurolidine or a derivative thereof, a prodrug, a solvate or a pharmaceutically acceptable salt thereof, or a composition containing the taurolidine or the derivative thereof, the prodrug, the solvate or the pharmaceutically acceptable salt thereof in preparation of antiviral drugs. Research results show that the taurolidine can significantly inhibit influenza virus and coronavirus at a cellular level. In addition, in-vivo experiments prove that taurolidine has a remarkable protection effect on lungs and can prolong the survival time of mice infected with influenza viruses or SARS-CoV-2 viruses. Therefore, the taurolidine can be used for preventing and treating lung diseases caused by the influenza virus or the coronavirus. The research result of the application expands the efficacy range of the taurolidine, and provides a research basis and opens up a new direction for research and development of drugs for preventing or treating pulmonary infection caused by the viruses.

Tumor metastases in cancer patients are inhibited by administration of a combination therapy including effective amounts of Interleukin-2 and a methylol transfer agent such as taurolidine, taurultam or mixtures thereof.

A method for treating Candida Auris in blood, comprising administering to the blood taurolidine, and / or one or more taurolidine derivatives, in a concentration which is effective to treat C. Auris in the blood.

Tumor metastases in cancer patients are inhibited by administration of a combination therapy including effective amounts of Interleukin-2 and a methylol transfer agent such as taurolidine, taurultam or mixtures thereof.

Methods and compositions for the treatment and / or prophylaxis and / or suppression of primary and / or secondary tumors of the central nervous system (brain and spinal cord, eyes) in mammalian subjects are disclosed, wherein an effective dose of a methylol transfer agent such as Taurolidine and / or Taurultam and / or a bioequivalent is administered to a mammalian subject suffering from, or at risk of growth of, tumors of the central nervous system. Furthermore, methods for local application of Taurolidine and / or Taurultam and / or a bioequivalent in solution are disclosed using microdialysis methods, irrigation methods, implantion methods and angiographic methods.

Neuroblastoma is a tumor primarily affecting children. The current standard of care is not curative except in the rare case of a surgically-resectable lesion, although very high survival rates have been documented for low-risk neuroblastoma and moderate-risk neuroblastoma. Taurolidine was developed as an anti-infective, but it has been found to have surprising oncolytic activity in cell cultures and now in a rodent cancer model. This invention relates to the use of taurolidine for the treatment of neuroblastoma in juvenile mammals.

A method of treating a patient suffering from TNBC by a multidisciplinary method involving treating the patient with a plurality of the following treatments: i) one or more checkpoint inhibitors; ii) hyperthermia treatment; iii) low dose chemotherapy; iv) Interleukin-2 (IL-2); and v) a compound selected from the group consisting of taurolidine, taurultam, oxathiazin-like compounds, and combinations thereof.